Analysis of treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer - a preliminary report

American Journal of Reproductive Immunology

Volumn 66, Issue 5, 2011, Pages 444-450

  Wicherek, Lukasz ^a,b   Jozwicki, Wojciech ^b   Windorbska, Wieslawa ^a   Roszkowski, Krzysztof ^a   Lukaszewska, Ewelina ^b   Wisniewski, Michal ^a   Brozyna, Anna Aneta ^b   Basta, Pawel ^a   Skret Magierlo, Joanna ^a   Koper, Krzysztof ^a,b   Rokita, Wojciech ^a   Dutsch Wicherek, Magdalena ^a  

^a Regional Oncology Centre Bydgoszcz   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Microenvironment; Ovarian cancer; Treg; Tumour

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE SUBPOPULATION; MENSTRUAL CYCLE; OVARY CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADENOCARCINOMA; AGED; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 80054048551     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2011.01024.x     Document Type: Article

References (32)

1. Feng L, Wang X: Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy. Chin Med J 2010; 123:3334-3342.
2. Wilczynski JR, Kalinka J, Radwan M: The role of the T-regulatory cells in pregnancy and cancer. Front Biosci 2008; 13:2275-2289.
3. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871-881.
4. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S: Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod 2004; 10:347-353.
5. Kingsley CL, Karim M, Bushell AR, Wood KJ: CD25+CD4+ regulatory T cells prevent graft rejection: CTLA4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168:1080-1086.
6. Hori S, Sakaguchi S: Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004; 6:745-751.
7. Saito S, Shiozaki A, Sasaki Y, Nakashima A, Shima T, Ito M: Regulatory T cells and regulatory NK cells play important roles in feto-maternal tolerance. Semin Immunopathol 2007; 29:115-122.
8. Tilburgs T, Roelen DL, van der Mast BJ, de Groot-Swings GM, Kleijburg C, Scherjon SA, Claas FH: Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol 2008; 180:5737-5745.
9. Arruvito L, Sanz M, Banham AH, Fainboim L: Expansion of CD4+CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol 2007; 178:2572-2578.
10. Schumacher A, Brachwitz N, Sohr S, Engeland K, Langwisch S, Dolaptchieva M, Alexander T, Taran A, Malfertheiner SF, Costa SD, Zimmermann G, Nitschke C, Volk HD, Alexander H, Gunzer M, Zenclussen AC: Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy. J Immunol 2009; 182:5488-5497.
11. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-213.
12. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-949.
13. Zhang P, Cote AL, de Varies VC: Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res 2007; 67:6468-6476.
14. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, Hawkins RE: Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56:1743-1753.
15. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, Pisa P: CD4-CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177:7398-7405.
16. Whiteside TL, Mandapathil M, Szczepanski M, Szajnik M: Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer 2011; 98:25-31.
17. Chu CS, Kim SH, June CH, Coukos G: Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008; 8:243-257.
18. Holschneider CH, Berek JS: Ovariancancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19:3-10.
19. Lage H: ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003; 22:188-199.
20. Salvadori S, Martinelli G, Zier K: Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000; 164:2214-2220.
21. Cole WH, Humphrey L: Need for immunologic stimulators during immunosupression produced by major cancer surgery. Ann Surg 1985; 202:920-925.
22. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS: A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13:98-107.
23. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W: FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69:3995-4000.
24. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061.
25. Galazka K, Wicherek L, Pitynski K, Kijowski J, Zajac K, Bednarek W, Dutsch-Wicherek M, Rytlewski K, Kalinka J, Basta A, Majka M: Changes in the subpopulation of CD25+ CD4+ and FOXP3+ regulatory T cells in decidua with respect to the progression of labor at term and the lack of analogical changes in the subpopulation of suppressive B7-H4 macrophages - a preliminary report. Am J Reprod Immunol 2009; 61:136-146.
26. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105:2862-2868.
27. Reinartz S, Pfisterer J, du Bois A, Jackisch C, Baumann KH, Wagner U: Suppressive activity rather than frequency of FoxP3- regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment. Hum Immunol 2010; 71:36-44.
28. Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N: Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009; 181:1894-1900.
29. Emens LA: Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci 2008; 13:249-257.
30. Chen R, Alvero AB, Silasi DA, Mor G: Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007; 57:93-107.
31. Garnett CT, Schlom J, Hodge JW: Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008; 14:3536-3544.
32. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM: Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009; 58:615-628.